Research ArticleNEUROPHARMACOLOGY
The Preclinical Pharmacological Profile of WAY-132983, a Potent M1 Preferring Agonist
Adam C. Bartolomeo, Herman Morris, Jerry J. Buccafusco, Nancy Kille, Sharon Rosenzweig-Lipson, Morris G. Husbands, Annmarie L. Sabb, Magid Abou-Gharbia, John A. Moyer and Carl A. Boast
Journal of Pharmacology and Experimental Therapeutics February 2000, 292 (2) 584-596;
Adam C. Bartolomeo
Herman Morris
Jerry J. Buccafusco
Nancy Kille
Sharon Rosenzweig-Lipson
Morris G. Husbands
Annmarie L. Sabb
Magid Abou-Gharbia
John A. Moyer
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 2
1 Feb 2000
Research ArticleNEUROPHARMACOLOGY
The Preclinical Pharmacological Profile of WAY-132983, a Potent M1 Preferring Agonist
Adam C. Bartolomeo, Herman Morris, Jerry J. Buccafusco, Nancy Kille, Sharon Rosenzweig-Lipson, Morris G. Husbands, Annmarie L. Sabb, Magid Abou-Gharbia, John A. Moyer and Carl A. Boast
Journal of Pharmacology and Experimental Therapeutics February 1, 2000, 292 (2) 584-596;
Research ArticleNEUROPHARMACOLOGY
The Preclinical Pharmacological Profile of WAY-132983, a Potent M1 Preferring Agonist
Adam C. Bartolomeo, Herman Morris, Jerry J. Buccafusco, Nancy Kille, Sharon Rosenzweig-Lipson, Morris G. Husbands, Annmarie L. Sabb, Magid Abou-Gharbia, John A. Moyer and Carl A. Boast
Journal of Pharmacology and Experimental Therapeutics February 1, 2000, 292 (2) 584-596;
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement